GIDM Rassegna 24, 107-115, 2004 ce of <strong>di</strong>agnostic serology. J Hepatol 35, 195-199, 2001 10. Braillon A, Capron JP, Herve MA, Degott C, Quenum C: Liver in obesity. Gut 26, 133-139, 1985 11. Nomura F, Ohnishi K, Satomura Y, Ohtsuki T, Fuk<strong>una</strong>ga K, Honda M et al: Liver function in moderate obesity: Study in 534 in moderately obese subjects among 4613 male company amployees. Int J Obes 10, 349-354, 1986 12. Silverman JF, O’Brien KF, Long S, Legget N, Khazanie PG, Pories WJ et al: Liver pathology in morbidly obese patients with and without <strong>di</strong>abetes. Am J Gastroenterol 85, 1345-1355, 1990 13. Angulo P, Keach JC, Batts KP, Lindor KD: In<strong>di</strong>pendent pre<strong>di</strong>ctors of liver fibrosis in patients with <strong>non</strong>-alcoholic steatohepatitis. Hepatology 30, 1356-1362, 1999 14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for gra<strong>di</strong>ng and staging of the histological lesions. Am J Gastroenterol 94, 2467-2474, 1999 15. Kral JG, Schaffner F, Pierson RN Jr, Wang J: Body fat topography as an in<strong>di</strong>pendent pre<strong>di</strong>ctor of fatty liver. Metabolism 42, 548-551, 1993 16. Yano E, Tagawa K, Yamaoka K, Mori M: Test vali<strong>di</strong>ty of perio<strong>di</strong>c liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 54, 945-951, 2001 17. Ricci C, Longo R, Gioulis E, Bosco M, Pallesello P, Masutti S et al: Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27, 108- 113, 1997 18. Mendler MH, Bouillet P, LeSidaner A, <strong>La</strong>vine E, <strong>La</strong>brousse F, Sautereau D et al: Dual-energy CT in the <strong>di</strong>agnosis and quantification of fatty liver limited clinical value in comparison to ultrasound scan and single energy CT, with special reference to iron overload. J Hepatol 28, 785-794, 1998 19. Szczepaniak LS, Babcock EE, Schick FD, Dobbins RL, Garg A, Burns TE et al: Measurement of intracellular triglyceride stores by H spectroscopy and validation in vivo. Am J Physiol 276, E977-E989, 1999 20. Day CP, James OFW: Steatohepatitis: a tale of two “hits”. Gastroenterology 114, 842-845, 1998 21. Uygun A, Kadayifei A, Yesiloua Z, Er<strong>di</strong>l A, Yaman H, Saka M et al: Serum leptin levels in patients with <strong>non</strong>-alcoholic steatohepatitis. Am J Gastroenterol 95, 3584- 3588, 2000 22. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A et al: Gene expression of TNF-α and TNF receptors, p55 and p75. J Hepatol 34, 1158-1163, 2001 23. Weyer C, F<strong>una</strong>hashi T, Tanaka S, Hotta K, Matsuzawa RE, Pratley PA et al: Hypoa<strong>di</strong>ponectinemia in obesity and type 2 <strong>di</strong>abetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935, 2001 24. Xu A, Wang Y, Keshaw H, Xu LY, <strong>La</strong>m KSL, Cooper GJS: The fat-derived hormone a<strong>di</strong>ponectin alleviates alcoholic and <strong>non</strong>-alcoholic fatty liver <strong>di</strong>sease in mice. J Clin Invest 112, 91-100, 2003 25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192, 2001 26. Festi D, Colecchia A, Sacco T, Bon<strong>di</strong> M, Roda E, Marchesini G: Hepatic <strong>steatosi</strong>s in obese patients: clinical meaning and prognostic significance. Obesity reviews (in stampa) 27. Chitturi S, George J: Interaction of iron, insulin resistance, and <strong>non</strong>alcoholic steatohepatitis. Curr Gastroenterol Rep 5, 18-25, 2003 28. Reid AE: Non-alcoholic steatohepatitis. Gastroenterology 121, 710-723, 2001 29. James OF, Day CP: Non-alcoholic steatohepatitis (NASH): a <strong>di</strong>sease of emerging identity and importance. J Hepatol 29, 495-501, 1998 30. Diehl AM, Goodman Z, Ishak KG: Alcohol-like liver <strong>di</strong>sease in <strong>non</strong>alcoholics: A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95, 1056-1062, 1988 31. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285, 2486-2497, 2001 32. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis obesity: a reversible con<strong>di</strong>tion. Acta Med Scand 220, 83-88, 1986 33. Andersen T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of <strong>di</strong>etary weight loss in morbidly obese subjects. J Hepatol 12, 224-229, 1991 34. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99, 1408-1413, 1990 35. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A: Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pe<strong>di</strong>atr 125, 239-241, 1994 36. Ueno T, Sugawara H, Sujako K, Hashimoto O, Tsuji R, Tamaki S et al: Therapeutic effects of restricted <strong>di</strong>et and exercise in obese patients with fatty liver. J Hepatol 27, 103-107, 1997 37. Franzese A, Vajro P, Argenziano A, Puziello A, Iannucci MP, Saviano MC et al: Liver involvement in obese children. Ultrasonography and liver enzyme levels at <strong>di</strong>agnosis and during follow-up in an Italian population. Dig Dis Sci 42, 1438-1442, 1997 38. Marchesini G, Brizi M, Bianchi G, Tomasetti S, Zoli M, Melchionda N: Metformin in <strong>non</strong>-alcoholic steatohepatitis (letter). <strong>La</strong>ncet 358, 893-894, 2001 39. Coyle WJ, Delaney N, Yoshihasi A, <strong>La</strong>wson P: Metformin treatment in patients with <strong>non</strong>alcoholic steatohepatitis normalizes LFTs and improves histology (abstract). Gastroenterology 116, A1198, 1999 40. Acosta RC, Molina EG, O’Brien CB, Cobo MC, Amaro R, Neff GW et al: The use of pioglitazone in <strong>non</strong>alcoholic steatohepatitis (abstract). Gastroenterology 120, A546, 114
GIDM Rassegna 24, 107-115, 2004 2001 41. Azuma T, Tomita K, Kato S, Adelchi M, Inokuchi N, Kitamura N et al: A pilot study of a thiazolideni<strong>di</strong>ones, pioglitazone, in <strong>non</strong>alcoholic steatohepatitis (abstract). Hepatology 36, 379A, 2002 42. Neuschwander-Tetri BA, Brunt EM, Sponseller C, Wehmeier KR, Hampton K. Histological improvement in NASH following increased insulin sensitivity with the PPAR-γ ligand rosiglitazone for 48 weeks (abstract). Hepatology 36, 379A, 2002 43. <strong>La</strong>urin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J et al: Ursodeoxycholic acid or clofibrate in the treatment of <strong>non</strong>-alcohol-induced steatohepatitis: a pilot study. Hepatology 23, 1464-1467, 1996 44. Horlander JC, Kwo PY, Cummings OW, Koukoulis G: Atorvastatin for the treatment of NASH (abstract). Gastroenterology 120, A544, 2001 45. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced <strong>non</strong>-alcoholic steatohepatitis (letter). <strong>La</strong>ncet 353, 1802, 1999 46. <strong>La</strong>vine JE: Vitamin E treatment of <strong>non</strong>alcoholic steatohepatitis in children. J Pe<strong>di</strong>atr 136, 734-738, 2000 47. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR: Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 98, 926-930, 2003 48. Desai TK, Chiorean M: Phlebotomy reduces transaminase levels in patients with chronic <strong>non</strong>alcoholic steatohepatitis (abstract). Gastroenterology 114, A1233, 1998 49. Nitecki J, Jackson FW, Allen ML, Farr VL, Jackson FW: Effect of phlebotomy on <strong>non</strong>-alcoholic steato-hepatitis (NASH) (abstract). Gastroenterology 118, A1474, 2000 50. Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of <strong>non</strong>alcoholic fatty liver <strong>di</strong>sease. Gastroenterology 122, 931-939, 2002 Corrispondenza a: Prof. Giulio Marchesini, Cattedra <strong>di</strong> Malattie del Metabolismo, “Alma Mater Stu<strong>di</strong>orum” Università <strong>di</strong> Bologna, Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna Pervenuto in Redazione il 23/12/2003 – Accettato per la pubblicazione il 28/1/2004 115
Change language